Drug Trial Radar · NCT04603508
Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
Last checked: Nov 19, 2026Latest source record: Aug 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
240
Planned (sponsor's estimate)
Start
Mar 2023
Primary completion
Apr 2025
Study completion Aug 2025
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Oct 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Berlim 25/10 association in the treatment of type 2 diabetes mellitus and dyslipidemia.
Conditions
- Type 2 Diabetes Mellitus
- Dyslipidemia
Interventions
BERLIM 25/10 associationDrug
Berlim 25/10 association coated tablet.
EMPAGLIFLOZINDrug
Empagliflozin 25 mg coated tablet.
ROSUVASTATIN CALCIUMDrug
Rosuvastatin 10 mg coated tablet.
BERLIM 25/10 ASSOCIATION PLACEBOOther
Berlim 25/10 association placebo coated tablet.
EMPAGLIFLOZIN PLACEBOOther
Empagliflozin placebo coated tablet.
ROSUVASTATIN CALCIUM PLACEBOOther
Rosuvastatin placebo coated tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in glycated hemoglobin (HbA1c) levels.Time frame: 120 days
- Percent change from baseline of LDL-c levels.Time frame: 120 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.